Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A protein-like 9 (TCEAL9) is a protein encoded by the TCEAL9 gene located on the X chromosome. It contains a domain similar to the transcription elongation factor A (SII)-related protein family and a WW domain that mediates protein-protein interactions, especially with polyproline ligands[1][3][6][10]. TCEAL9 may be involved in transcriptional regulation by acting as a WW domain-binding protein, suggesting a role in controlling gene expression[3][6][10]. Alternative splicing leads to multiple transcripts but a single protein isoform. Elevated expression of TCEAL9/WBP5 has been associated with poor prognosis in certain malignancies, such as acute myeloid leukemia, though it is not currently a validated therapeutic target[9]. No drugs are known to modulate TCEAL9 specifically, and its function is the subject of ongoing research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A protein-like 9 (TCEAL9).